• 1
    Takahashi S, Yamada Y, Homma Y, Horie S, Hosaka Y, Kitamura T. Power Doppler ultrasonography-dirceted prostate biopsy in men with elevated serum PSA levels: an evaluation of the clinical utility and limitations. Urology 2002; 60: 24852
  • 2
    Catalona WJ, Richie JP, De Kernion JB et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 20316
  • 3
    Stenman UH, Abrahamsson PA, Aus G et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl 2005; 216: 6481
  • 4
    Luboldt HJ, Bex A, Swoboda A, Husing J, Rubben H. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/mL prostate-specific antigen as cutoff. Eur Urol 2001; 39: 1317
  • 5
    Cervera Deval J, Gonzalez Anon M, Martin Diez F, Jornet Fayos J, Morales Olaya FJ, Selfa Moreno S. Utility of local anesthesia of the periprostatic plexus in the control of the pain in the ultrasound-guided prostate biopsy. Actas Urol Esp 2005; 29: 9437
  • 6
    Schamhart DH, Maiazza R, Kurt KH. Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology. Int J Oncol 2005; 26: 56577
  • 7
    Fehm T, Sagalowsky A, Clifford E et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002; 8: 207384
  • 8
    Schmidt H, De Angelis G, Bettendorf O et al. Frequent detection and immunophenotyping of prostate-derived cell clusters in the peripheral blood of prostate cancer patients. Int J Biol Markers 2004; 19: 939
  • 9
    Brandt B, Junker R, Griwatz C et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res 1996; 56: 455661
  • 10
    Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, Ts’o PO. Identification and characterization of circulating prostate carcinoma cells. Cancer 2000; 88: 278795
  • 11
    Schmitt M, Harbeck N, Daidone MG et al. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol 2004; 25: 1397406
  • 12
    Austrup F, Uciechowski P, Eder C et al. Prognostic value of genomic alterations in minimal residual cancer cells purified from blood of breast cancer patients. Br J Cancer 2000; 83: 166473
  • 13
    Giesing M, Austrup F, Böckmann B et al. Independent prognostication and therapy monitoring of breast cancer patients by DNA/RNA typing of minimal residual cancer cells. Int J Biol Markers 2000; 15: 949
  • 14
    Fehm T, Solomayer EF, Meng S et al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7: 17185
  • 15
    Dong JT, Isaacs WB, Barrett JC, Isaacs JT. Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics 1997; 41: 2532
  • 16
    Cunningham JM, Shan A, Wick MJ et al. Allelic imbalances and microsatellite instability in prostate adenocarcinoma. Cancer Res 1996; 56: 447582
  • 17
    Suchy B, Austrup F, Driesel G et al. Detection of mammaglobin expressing cells in blood of breast cancer patients. Cancer Lett 2000; 158: 1718
  • 18
    Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The metastatic cascade in prostate cancer. Surg Oncol 2006; 15: 11728
  • 19
    Thomas J, Gupta M, Grasso Y et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 2002; 20: 32138
  • 20
    Straub B, Muller M, Krause H et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using ‘Light-Cycler’-based quantitative real-time polymerase chain reaction. Urology 2001; 58: 81520
  • 21
    Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003; 61: 27781
  • 22
    Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 825361
  • 23
    Rosner IL, Ravindranath L, Furusato B et al. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology 2007; 70: 12259
  • 24
    Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006; 25: 695705
  • 25
    Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effect on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001; 3: 3237
  • 26
    Petros JA, Baumann AK, Ruiz-Pesini E et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 2005; 102: 71924
  • 27
    Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 2006; 103: 155405
  • 28
    Mohler JL, Morris TL, Ford OH III , Alvey RF, Sakamoto C, Gregory CW. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 2002; 51: 24755
  • 29
    Venkataraman S, Jiang X, Weydert C et al. Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 2005; 24: 7789
  • 30
    Bostwick DG, Alexander EE, Singh R et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000; 89: 12334
  • 31
    Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006; 25: 15549
  • 32
    Gouaze V, Andrieu-Abadie N, Cuvillier O et al. Glutathione peroxidase-1 protects from CD95-induced apoptosis. J Biol Chem 2002; 277: 4286774
  • 33
    Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine – a new perspective for detecting prostate cancer. Eur Urol 2004; 46: 1827
  • 34
    Leonard S, Marks MD, David G, Bostwick MD. Prostate cancer specifity of PCA3 gene testing: examples from clinical practice. Rev Urol 2008; 10: 17581
  • 35
    Schostak M, Schwall GP, Poznanovic S et al. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol 2009; 181: 34353
  • 36
    Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 9104
  • 37
    Roupret M, Hupertan V, Yates DR et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007; 13: 17205
  • 38
    Davis JW, Nakanishi H, Kumar VS et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 2008; 179: 218791
  • 39
    De Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 63029
  • 40
    Scher HI, Jia X, De Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 2339